Endometriosis Pipeline Drugs Analysis Report, 2024: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Organon, Ironwood Pharma, AbbVie/Neurocrine Biosciences, Mitsubishi Tanabe

The Endometriosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Endometriosis Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Endometriosis Market.

Some of the key takeaways from the Endometriosis Pipeline Report:

• Companies across the globe are diligently working toward developing novel Endometriosis treatment therapies with a considerable amount of success over the years. 

• Endometriosis companies working in the treatment market are Nanjing Chia-tai Tianqing Pharmaceutical, Hera Biotech, Inc., Bio Genuine (Shanghai) Biotech Co., Ltd., Sumitomo Pharma Switzerland GmbH, Organon, Ironwood Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, AbbVie/Neurocrine Biosciences, ObsEva/Kissei Pharmaceuticals, SWK/Enteris BioPharma, Bayer/Hope Medicine, Tiumbio, and others, are developing therapies for the Endometriosis treatment 

• Emerging Endometriosis therapies in the different phases of clinical trials are – Elagolix, MetriDx, BG2109, Relugolix Combination Tablet, FOR 6219, IW-3300, MT-2990, ORIAHNN (elagolix/estradiol/norethindrone acetate), Linzagolix (OBE2109), OVAREST (leuprorelin oral), HMI-115, TU2670 (NCE-403), OG-6219, and others are expected to have a significant impact on the Endometriosis market in the coming years.  

• In March 2024, By the end of this year, Gynica, headquartered in Israel, plans to administer the first dose to a patient in a Phase I trial evaluating its cannabinoid-based treatments, IntraVagS301 and IntraVagS302, for endometriosis.

• In April 2022, A MoH application for HMI-115 was received in the first European nation.

• ObsEva has a partnership with Syneos for the American market’s commercialization of linzagolix, and a licencing deal with Theramex for the international markets outside of North America, Asia, and Europe.

Endometriosis Overview

Endometriosis is a condition marked by the uncontrolled expansion of tissue that resembles endometrium outside the uterus. When a woman is not pregnant, endometrial tissue naturally borders the uterus and thickens and degrades as part of the monthly cycle. The abnormal growths, or lesions, typically form on or around the reproductive organs, on the bowels, or on the bladder, however they can form anywhere.

Get a Free Sample PDF Report to know more about Endometriosis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/endometriosis-pipeline-insight

Emerging Endometriosis Drugs Under Different Phases of Clinical Development Include:

• Elagolix: Nanjing Chia-tai Tianqing Pharmaceutical

• MetriDx: Hera Biotech, Inc.

• BG2109: Bio Genuine (Shanghai) Biotech Co., Ltd.

• Relugolix Combination Tablet: Sumitomo Pharma Switzerland GmbH

• FOR 6219: Organon

• IW-3300: Ironwood Pharmaceuticals

• MT-2990: Mitsubishi Tanabe Pharma Corporation

• ORIAHNN (elagolix/estradiol/norethindrone acetate): AbbVie/Neurocrine Biosciences

• Linzagolix (OBE2109): ObsEva/Kissei Pharmaceuticals

• OVAREST (leuprorelin oral): SWK/Enteris BioPharma

• HMI-115: Bayer/Hope Medicine

• TU2670 (NCE-403): Tiumbio

• OG-6219: Organon

• Quinagolide: Ferring Pharmaceuticals

• Linzagolix: ObsEva

Endometriosis Route of Administration

Endometriosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Inhalation

• Inhalation/Intravenous/Oral

• Intranasal

• Intravenous

• Intravenous/ Subcutaneous

• NA

• Oral

• Oral/intranasal/subcutaneous

• Parenteral

• Subcutaneous

Endometriosis Molecule Type

Endometriosis Products have been categorized under various Molecule types, such as

• Antibody

• Antisense oligonucleotides

• Immunotherapy

• Monoclonal antibody

• Peptides

• Protein

• Recombinant protein

• Small molecule

• Stem Cell

• Vaccine

Endometriosis Pipeline Therapeutics Assessment

• Endometriosis Assessment by Product Type

• Endometriosis By Stage and Product Type

• Endometriosis Assessment by Route of Administration

• Endometriosis By Stage and Route of Administration

• Endometriosis Assessment by Molecule Type

• Endometriosis by Stage and Molecule Type

DelveInsight’s Endometriosis Report covers around 20+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Endometriosis product details are provided in the report. Download the Endometriosis pipeline report to learn more about the emerging Endometriosis therapies

Some of the key companies in the Endometriosis Therapeutics Market include:

Key companies developing therapies for Endometriosis are – AbbVie, Neurocrine Biosciences, Kissei Pharmaceuticals, SWK, Enteris BioPharma, Bayer, Hope Medicine, Tiumbio, Organon, Ferring Pharmaceuticals, ObsEva SA, Myovant Sciences, Hope Medicine (Nanjing) Co., Ltd, TiumBio Co., Ltd., Mitsubishi Tanabe Pharma, and others.

Endometriosis Pipeline Analysis:

The Endometriosis pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Endometriosis with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Endometriosis Treatment.

• Endometriosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Endometriosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Endometriosis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Endometriosis drugs and therapies

Endometriosis Pipeline Market Drivers 

• The development of drug delivery systems represents a new approach in pain treatment among endometriosis patients, extensive research on Non-steroidal anti-inflammatory drugs are some of the important factors that are fueling the Endometriosis Market.

Endometriosis Pipeline Market Barriers

• However, less robust pipeline, high cost of treatment procedures and other factors are creating obstacles in the Endometriosis Market growth.

Scope of Endometriosis Pipeline Drug Insight    

• Coverage: Global

• Key Endometriosis Companies: Nanjing Chia-tai Tianqing Pharmaceutical, Hera Biotech, Inc., Bio Genuine (Shanghai) Biotech Co., Ltd., Sumitomo Pharma Switzerland GmbH, Organon, Ironwood Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, AbbVie/Neurocrine Biosciences, ObsEva/Kissei Pharmaceuticals, SWK/Enteris BioPharma, Bayer/Hope Medicine, Tiumbio, and others

• Key Endometriosis Therapies: Elagolix, MetriDx, BG2109, Relugolix Combination Tablet, FOR 6219, IW-3300, MT-2990, ORIAHNN (elagolix/estradiol/norethindrone acetate), Linzagolix (OBE2109), OVAREST (leuprorelin oral), HMI-115, TU2670 (NCE-403), OG-6219, and others

• Endometriosis Therapeutic Assessment: Endometriosis current marketed and Endometriosis emerging therapies

• Endometriosis Market Dynamics: Endometriosis market drivers and Endometriosis market barriers 

Request for Sample PDF Report for Endometriosis Pipeline Assessment and clinical trials

Table of Contents 

1. Endometriosis Report Introduction

2. Endometriosis Executive Summary

3. Endometriosis Overview

4. Endometriosis- Analytical Perspective In-depth Commercial Assessment

5. Endometriosis Pipeline Therapeutics

6. Endometriosis Late Stage Products (Phase II/III)

7. Endometriosis Mid Stage Products (Phase II)

8. Endometriosis Early Stage Products (Phase I)

9. Endometriosis Preclinical Stage Products

10. Endometriosis Therapeutics Assessment

11. Endometriosis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Endometriosis Key Companies

14. Endometriosis Key Products

15. Endometriosis Unmet Needs

16 . Endometriosis Market Drivers and Barriers

17. Endometriosis Future Perspectives and Conclusion

18. Endometriosis Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/